All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Pre-emptive versus prophylactic use of TKIs after allo-SCT in patients with Philadelphia chromosome-positive ALL

Jul 28, 2021
Share:

Tyrosine kinase inhibitors (TKIs) targeting the BCR-ABL fusion gene product have revolutionized therapy for patients with BCR-ABL/Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL); however, it is unclear if outcomes are improved with the use of TKIs as maintenance therapy after allogeneic stem cell transplantation (allo-SCT). During the 26th Congress of the European Hematology Association (EHA2021), Anna Candoni discussed the results of a retrospective subanalysis of the Italian Group for Blood and Marrow Transplantation Nurses Group (GITMO) trial (NCT03821727), to examine the effect of different strategies of posttransplant TKI treatment for Ph+ ALL.1

Study design

The GITMO trial included 441 patients with Ph+ ALL who were undergoing SCT and had been treated with TKIs in the induction phase.

Eligibility criteria:

  • Only patients in morphological complete remission before SCT.
  • Patients had to be receiving TKI treatment post-allo-SCT.
  • Patients were excluded if they were in cytological relapse (n = 41).

Patients were included regardless of their pre-transplant measurable residual disease (MRD) status. One group of patients were given TKIs prophylactically after allo-SCT, starting when they were MRD-negative. The second group of patients were given TKIs post-allo-SCT, starting at the first time they were found to be MRD-positive (pre-emptive group).

The aim of the study was to assess overall survival (OS) and disease-free survival (DFS) of the patients in the two TKI-treated groups.

The characteristics of patients selected for this subanalysis are shown in Table 1. Of the 122 patients included, 30% were MRD-negative prior to allo-SCT. The pre-emptive TKI group comprised 62 MRD-positive patients and 25 MRD-negative patients. The prophylactic group had 23 MRD-positive patients and 12 MRD-negative patients.

The median age for the whole cohort was 43 years (18.6−67.3) and 50% were female. Other characteristics were comparable between the two groups. Most patients in both groups either underwent matched unrelated donor transplant or received a human leukocyte antigen-identical transplant.

Table 1. Patient characteristics*

Characteristic

N = 122

Pre-emptive TKI
(n = 87)

Prophylactic TKI
(n = 35)

EBMT risk score, %

              1−2

49

46

54

              ≥3

51

54

46

Allo-SCT, %

              MUD

44

43

46

              HLA-id

47

48

40

              Haplo

7

6

11

              Cord blood

2

3

3

TBI, %

48

47

49

ATG, %

57

58

54

Allo-SCT, allogeneic stem cell transplant; ATG, antithymocyte globulin; EBMT, European Group for Blood and Marrow Transplantation; Haplo, haploidentical; HLA-id, human leukocyte antigen-identical; MUD, matched unrelated donor; TBI, total body irradiation; TKI, tyrosine kinase inhibitor.
*Adapted from Candoni et al.1

Results

TKI treatment was initiated at significantly different times for the two groups; patients treated pre-emptively started TKI treatment with a median of 4.37 months after transplantation, whereas prophylactic treatment started with a median of 2.97 months after transplantation (p = 0.01).

There was no significant difference in the firstline TKI agent used amongst the two groups. Of the TKIs administered (imatinib, dasatinib, ponatinib, or nilotinib), most patients received imatinib (45.5%) or dasatinib (41%). Overall, the percentage of patients who received secondline TKI treatment was not significantly different between groups (31% in the prophylaxis group, and 46% in the pre-emptive group). However, there was a difference in the number of patients who received secondline TKI therapy for cytological relapse or MRD-positive status; in the prophylactic group, 27% received a TKI following a relapse compared with 69% in the pre-emptive group (p = 0.01). The median TKI duration was 12.5 months (range, 5.9−20.5) in the prophylactic group and 12.2 months (range, 3.2−78.8) in the pre-emptive group.

The results for OS were:

  • Prophylactic TKIs, 5-year OS was 72% (median OS was not reached).
  • Pre-emptive TKIs, 5-year OS was 58% (median OS of 62 months, p = 0.07).

The results for DFS were:

  • Prophylactic 5-year DFS was 72% (median DFS not reached).
  • Pre-emptive 5-year DFS was 47% (median DFS of 36 months, p = 0.002).

In the prophylactic group only 17% of patients experienced a cytological relapse compared to 49.4% in the pre-emptive group (p = 0.0001).

Patients who were treated with prophylactic TKIs demonstrated significantly longer DFS regardless of their MRD status prior to SCT compared with patients treated pre-emptively (p < 0.001).

Conclusion

The results of this subanalysis suggest that a prophylactic TKI treatment strategy after allo-SCT may be a viable option for patients with Ph+ ALL, with good OS and DFS achieved in this setting. In addition, regardless of MRD status before SCT, a prophylactic TKI treatment strategy led to a better DFS than a pre-emptive treatment strategy.

  1. Candoni A, Lazzarotto D, Bonifazi F, et al. Prophylactic or pre-emptive use of tyrosine kinase inhibitors post-allogeneic stem cell transplantation in BCR-ABL positive acute lymphoblastic leukemia: A subanalysis of GITMO Ph-positive ALL study. Oral abstract #p428-1. EHA2021; June 9−17, 2021; Virtual.

Share: